#1 Clinical Trials Search in Europe

Busulfan

Busulfan is a chemotherapy drug that has been extensively studied in clinical trials for its use in stem cell transplantation and cancer treatment. This article examines several clinical trials investigating busulfan-based conditioning regimens prior to stem cell transplantation in various patient populations, including those with leukemia, multiple myeloma, and genetic rare diseases. The trials aim to optimize busulfan dosing, evaluate its efficacy and safety compared to other conditioning regimens, and assess outcomes in specific patient groups.

Table of Contents

What is Busulfan?

Busulfan is a powerful medication used in cancer treatment, particularly before stem cell transplants. It’s also known by brand names such as Busulfex and Myleran[1]. This drug plays a crucial role in preparing a patient’s body for a stem cell transplant by destroying existing bone marrow cells to make room for new, healthy cells[1].

What Conditions Does Busulfan Treat?

Busulfan is primarily used in the treatment of several blood-related cancers and disorders, including:

  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow[2]
  • Myelodysplastic Syndrome (MDS): A group of disorders where blood cells don’t mature properly in the bone marrow[1]
  • Chronic Myeloid Leukemia (CML): A slow-growing type of blood cancer[3]
  • Multiple Myeloma: A cancer of plasma cells, a type of white blood cell[4]
  • Non-Hodgkin’s Lymphoma: A type of cancer that affects the lymphatic system[5]

Additionally, Busulfan is used in the treatment of certain inherited metabolic disorders, such as adrenoleukodystrophy and Hurler syndrome, before stem cell transplantation[6].

How Does Busulfan Work?

Busulfan belongs to a class of drugs called alkylating agents. It works by damaging the DNA of cells, which prevents them from dividing and ultimately leads to cell death. In the context of stem cell transplantation, Busulfan is used to destroy the patient’s existing bone marrow cells. This process, known as myeloablation, creates space for the new, healthy stem cells to engraft and begin producing normal blood cells[1].

How is Busulfan Administered?

Busulfan is typically administered intravenously (through a vein) in a hospital setting. The dosage and schedule can vary depending on the specific treatment plan, but it’s often given over several days before a stem cell transplant. For example, one common regimen involves administering Busulfan four times a day for four consecutive days[1].

Busulfan in Combination Therapies

Busulfan is frequently used in combination with other medications to prepare patients for stem cell transplantation. Some common combination therapies include:

  • Busulfan and Cyclophosphamide (BuCy2): This is considered a standard conditioning regimen for many types of stem cell transplants[2]
  • Busulfan and Fludarabine (BuFlu): This combination is often used as a reduced-toxicity conditioning regimen, especially for older patients or those with certain health conditions[2]
  • Busulfan, Cyclophosphamide, and Melphalan: This three-drug combination is being studied for its potential to improve outcomes in certain types of leukemia and myelodysplastic syndrome[1]

Potential Side Effects and Risks

As with any powerful medication, Busulfan can cause side effects. Some potential side effects include:

  • Nausea and vomiting
  • Mouth sores
  • Diarrhea
  • Hair loss
  • Increased risk of infections
  • Liver problems
  • Lung problems (rare but serious)

One serious potential complication is veno-occlusive disease (VOD), a condition where small veins in the liver become blocked. Your healthcare team will monitor you closely for any signs of this or other serious side effects[2].

Current Research and Clinical Trials

Researchers continue to study Busulfan to find ways to improve its effectiveness and reduce side effects. Some areas of current research include:

  • Comparing different combination therapies to find the most effective and least toxic regimens[2]
  • Studying the use of Busulfan in reduced-intensity conditioning regimens for older patients or those with certain health conditions[2]
  • Investigating the use of Busulfan in treating various inherited metabolic disorders[6]
  • Exploring ways to prevent or reduce the risk of complications like veno-occlusive disease[2]

If you’re considering treatment with Busulfan, your healthcare team will discuss the potential benefits and risks with you, as well as any relevant ongoing clinical trials that you might be eligible for.

Trial Focus Patient Population Key Interventions Primary Outcomes
Busulfan vs Cyclophosphamide in AML AML patients aged 40-65 Busulfan+Fludarabine vs Busulfan+Cyclophosphamide Transplant-related mortality at 1 year
Busulfan in Multiple Myeloma Patients ≥65 or with renal insufficiency Escalating doses of IV Busulfan Maximum tolerated dose of Busulfan
Busulfan vs Treosulfan in pediatrics Children with non-malignant diseases Treosulfan-based vs Busulfan-based conditioning Freedom from transplant-related mortality
Busulfan pharmacokinetics Adult patients with acute leukemia IV Busulfan with PK monitoring Area under the curve (AUC) of Busulfan
Targeted Busulfan in ALL Children and adolescents with ALL Targeted Busulfan+Fludarabine+Etoposide 1-year event-free survival

FAQ

  • What is busulfan used for in clinical trials? Busulfan is primarily used as part of conditioning regimens before stem cell transplantation. It is being studied in patients with acute myeloid leukemia, multiple myeloma, acute lymphoblastic leukemia, and genetic rare diseases.
  • Why is optimizing busulfan dosing important? Busulfan has a narrow therapeutic window. High exposure can lead to toxicity like veno-occlusive disease, while low exposure may result in graft failure or disease relapse. Optimizing the dose through pharmacokinetic studies aims to improve transplant outcomes.
  • How does busulfan compare to other conditioning regimens? Some trials are comparing busulfan-based regimens to traditional ones like cyclophosphamide or melphalan. For example, one study is evaluating if busulfan plus fludarabine results in lower transplant-related mortality compared to busulfan plus cyclophosphamide in AML patients.
  • What patient populations are being studied with busulfan? Clinical trials are investigating busulfan use in various groups, including elderly patients (over 65), those with renal insufficiency, children and adolescents with leukemia, and patients with genetic rare diseases undergoing stem cell transplantation.
  • What are some key outcomes being measured in these trials? Key outcomes include transplant-related mortality, engraftment rates, overall survival, progression-free survival, toxicity profiles, incidence of graft-versus-host disease, and pharmacokinetic parameters of busulfan.

Ongoing Clinical Trials on Busulfan

  • Study on the Effects of Exagamglogene Autotemcel for Patients with Transfusion-Dependent Beta-Thalassemia or Severe Sickle Cell Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Italy

  • Study on Conditioning Treatments with Busulfan, Clofarabine, and Fludarabine for Children with Acute Myeloid Leukemia Undergoing Stem Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark Finland Lithuania The Netherlands Norway +1

  • Study Comparing Clofarabine/Busulfan and Fludarabine/Busulfan for Adults with Acute Myeloid Leukemia Eligible for Stem Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    France

  • Study on Allogeneic Stem Cell Transplantation for Children and Adolescents with Acute Lymphoblastic Leukemia Using Etoposide, Treosulfan, and Thiotepa

    Recruiting

    4 1 1 1
    Investigated Drugs:
    Austria Belgium Czechia Denmark France Germany +6

  • Study on the Use of OTL-103 Gene Therapy and Drug Combination for Patients with Wiskott-Aldrich Syndrome

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy

  • Study on the Effectiveness and Safety of Exa-cel for Adolescents and Adults with Severe Sickle Cell Disease

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Czechia Germany Greece Italy Poland

  • Study on Melphalan and Drug Combination for Low and Intermediate Risk Neuroblastoma Patients

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    Germany

  • Study of gemtuzumab ozogamicin and chemotherapy combinations in children with newly diagnosed acute myeloid leukemia, high-risk myelodysplastic syndrome, or myeloid sarcoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Ireland

  • Study on Gene Therapy with Autologous Stem Cells and Drug Combination for Children with Mucopolysaccharidosis Type I Hurler Variant

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Italy

Glossary

  • Allogeneic hematopoietic stem cell transplantation (HSCT): A procedure where a patient receives blood-forming stem cells from a genetically similar, but not identical, donor to replace diseased or damaged bone marrow.
  • Conditioning regimen: A treatment plan using chemotherapy and/or radiation therapy to prepare a patient's body for stem cell transplantation by destroying diseased cells and suppressing the immune system.
  • Busulfan: A chemotherapy drug used in conditioning regimens before stem cell transplantation, often in combination with other medications.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Veno-occlusive disease (VOD): A potentially serious liver complication that can occur after stem cell transplantation, characterized by blocked small veins in the liver.
  • Graft-versus-host disease (GVHD): A condition where donor immune cells attack the recipient's tissues, which can occur after allogeneic stem cell transplantation.
  • Engraftment: The process by which transplanted stem cells start to produce new blood cells in the recipient's body.
  • Transplant-related mortality (TRM): Deaths caused by complications of the transplant procedure, rather than from the underlying disease.
  • Myeloablative conditioning: An intense form of conditioning that destroys most or all of the bone marrow cells before transplantation.
  • Reduced-intensity conditioning (RIC): A less intense form of conditioning that partially destroys the bone marrow, allowing older or less fit patients to undergo transplantation.

References

  1. https://clinicaltrials.gov/study/NCT00176839
  2. https://clinicaltrials.gov/study/NCT01191957
  3. https://clinicaltrials.gov/study/NCT01366612
  4. https://clinicaltrials.gov/study/NCT01923935
  5. https://clinicaltrials.gov/study/NCT00582933
  6. https://clinicaltrials.gov/study/NCT00176904